In postmenopausal osteoporosis, the alendronate sequence produced the largest BMD increase in all regions over 30 months.
In plain wordsIn postmenopausal osteoporosis, bone density increased most with the alendronate sequence compared with the other sequences.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- IncreaseOverall regional BMD across treatment sequences
- Study
n = 125
- Comparator
- Raloxifene sequence and teriparatide monotherapy sequence
- Outcome group
- Bone and joint · Musculoskeletal
Source sentences
Analyzing the entire 30 months of therapy, the ALN group revealed the largest BMD increase in all regions.
2 context sentences(design, population, supporting numbers)
Postmenopausal women (n = 125) with severe osteoporosis on ongoing TPTD treatment for 9 months were randomized into three open-label groups for another 9 months: ALN (70 mg/week, n = 41), RAL (60 mg/d, n = 37) in addition to TPTD or no additional medication (n = 47) except Ca and vitamin D.
After discontinuation of TPTD the respective antiresorptives were continued for a further 12 months, while patients in the TPTD monotherapy group received Ca and vitamin D.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).